1887

n Cardiovascular Journal of South Africa - Teveten(R) (eprosartan) reduces future risk in hypertensive stroke patients : drug trends in cardiology

Volume 15, Issue 5
  • ISSN : 1680-0745
USD

 

Abstract

Extracted from text ... The established antihypertensive agent Teveten(r) (eprosartan) has now been shown to offer effective protection against cerebrovascular and cardiovascular events in hypertensive patients with a previous stroke, over and above that offered by blood pressure reduction. Initial results from the landmark MOSES* study, presented by Professor Joachim Schrader at the XXVI Congress of the European Society of Cardiology in Munich, showed that blood pressure was equally well controlled when hypertensive patients with a history of stroke were treated with either eprosartan-based or nitrendipinebased therapies. However, there was a significant reduction of 20% in the primary endpoint (total mortality and total cardiovascular ..

Loading full text...

Full text loading...

Loading

Article metrics loading...

/content/cardio/15/5/EJC23938
2004-09-01
2017-06-23

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error